Kinnate Biopharma Performance
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
The company secures a Beta (Market Risk) of -1.66, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Kinnate Biopharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Kinnate Biopharma is expected to outperform it. Kinnate Biopharma right now secures a risk of 0.0%. Please verify Kinnate Biopharma potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if Kinnate Biopharma will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kinnate Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Kinnate Biopharma is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 55 M |
Kinnate |
Kinnate Biopharma Relative Risk vs. Return Landscape
If you would invest 296.00 in Kinnate Biopharma on August 27, 2024 and sell it today you would earn a total of 0.00 from holding Kinnate Biopharma or generate 0.0% return on investment over 90 days. Kinnate Biopharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Kinnate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kinnate Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kinnate Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kinnate Biopharma, and traders can use it to determine the average amount a Kinnate Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| KNTE |
Based on monthly moving average Kinnate Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kinnate Biopharma by adding Kinnate Biopharma to a well-diversified portfolio.
Kinnate Biopharma Fundamentals Growth
Kinnate Stock prices reflect investors' perceptions of the future prospects and financial health of Kinnate Biopharma, and Kinnate Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kinnate Stock performance.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (25.71 M) | |||
| Shares Outstanding | 47.17 M | |||
| Price To Book | 0.79 X | |||
| EBITDA | (118.21 M) | |||
| Cash And Equivalents | 262.42 M | |||
| Cash Per Share | 5.94 X | |||
| Total Debt | 3.17 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 3.66 X | |||
| Cash Flow From Operations | (100.04 M) | |||
| Earnings Per Share | (2.78) X | |||
| Total Asset | 173.6 M | |||
| Retained Earnings | (372.01 M) | |||
About Kinnate Biopharma Performance
By analyzing Kinnate Biopharma's fundamental ratios, stakeholders can gain valuable insights into Kinnate Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kinnate Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kinnate Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Kinnate Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.Things to note about Kinnate Biopharma performance evaluation
Checking the ongoing alerts about Kinnate Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kinnate Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kinnate Biopharma is not yet fully synchronised with the market data | |
| Kinnate Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (112.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kinnate Biopharma currently holds about 262.42 M in cash with (100.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are owned by institutional investors |
- Analyzing Kinnate Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kinnate Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Kinnate Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kinnate Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kinnate Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kinnate Biopharma's stock. These opinions can provide insight into Kinnate Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |